In a phase 2a trial of 20 patients with moderately-to-severely active ulcerative colitis, SB012 enemas for 4 weeks did not significantly change Total Mayo Score vs placebo (primary outcome); SB012 was well tolerated.
RCTn = 20
Atreya et al. Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial